Regenxbio (RGNX) Tax Provisions (2018 - 2022)

Regenxbio's Tax Provisions history runs 5 years deep, the most recent figure standing at -$58.8 million for Q4 2022.

• On a quarterly basis, Tax Provisions fell 539.04% year-over-year to -$58.8 million in Q4 2022; TTM through Dec 2022 was -$58.9 million, a 539.21% decrease from a year earlier, with the FY2024 full-year figure at $3.5 million, up 2404.61% from the prior year.
• Tax Provisions fell to -$58.8 million in Q4 2022 per RGNX's latest filing, from -$41000.0 in the prior quarter.
• Across five years, Tax Provisions topped out at $13.4 million in Q4 2021 and bottomed at -$58.8 million in Q4 2022.
• The 5-year median for Tax Provisions is -$22000.0 (2020), against an average of -$4.0 million.
• Across the five-year window, Tax Provisions slumped 1340.53% in 2019 and jumped 133.38% in 2021, its largest moves.
• Year by year, Tax Provisions stood at $1.6 million in 2018, then slumped by 1340.53% to -$20.1 million in 2019, then soared by 128.56% to $5.7 million in 2020, then jumped by 133.38% to $13.4 million in 2021, then sank by 539.04% to -$58.8 million in 2022.
• Per Business Quant, the three latest RGNX Tax Provisions figures stand at -$58.8 million (Q4 2022), -$41000.0 (Q1 2022), and $13.4 million (Q4 2021).